Restoring lysosomal proteostasis reverses steatohepatitis and fibrosis in experimental MASH.
The data indicate that this pharmacological restoration of lysosomal proteostasis engages key transcriptional regulators (Mediator complex) leading to the selective remodeling of pro-fibrotic and inflammatory pathways, leading to the selective remodeling of pro-fibrotic and inflammatory pathways.